In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”-Reference-Cited by-同舟云学术

In Response to: “Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?”

Published:2022-02 Issue:2 Volume:17 Page:e12-e14
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Thomas Nicholas J.,Myall Nathaniel J.,Sun Fangdi,Patil Tejas,Mushtaq Rao,Yu Chandler,Sinha Sumi,Pollom Erqi L.,Nagpal Seema,Camidge D. Ross,Rusthoven Chad G.,Braunstein Steve E.,Wakelee Heather A.,McCoach Caroline E.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Comparing addition of radiotherapy in EGFR- and ALK-positive non-small cell lung cancer with brain metastases: are we evaluating the optimal endpoint?;Nardone;J Thoracic Oncol,2022

2. Thomas NJ, Myall NJ, Sun F, et al. Brain metastases in EGFR- and ALK-positive non-small cell lung cancer: outcomes of CNS penetrant tyrosine kinase inhibitors (TKIs) alone versus in combination with radiation [e-pub ahead of print]. J Thorac Oncol. 2022:116-129. https://doi.org/10.1016/j.jtho.2021.08.009, accessed August 26, 2021.

3. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis;Magnuson;J Clin Oncol,2017

4. CNS response to Osimertinib versus Standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR -mutated advanced non–small-cell lung cancer;Reungwetwattana;J Clin Oncol,2018

5. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study;Mok;Ann Oncol,2020